Is BIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BIO. It does not provide personalized investment advice.

BIO (Bio-Rad Laboratories, Inc.Class A) Stock Analysis - Financials

Bio-Rad Laboratories, Inc.Class A (BIO) is a publicly traded Healthcare sector company. As of July 23, 2026, BIO trades at $313.11 with a market cap of $8.07B and a P/E ratio of 10.97. BIO moved +2.58% today. Year to date, BIO is +0.98%; over the trailing twelve months it is +24.64%. Its 52-week range spans $211.43 to $373.69. Analyst consensus is buy with an average price target of $301.67. Rallies surfaces BIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are BIO's key financials?

BIO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BIO recently traded at $313.11. Market cap is $8.07B. P/E ratio is 10.97. Revenue is $2.58B.

BIO Key Metrics

Key financial metrics for BIO
Metric	Value
Price	$313.11
Market Cap	$8.07B
P/E Ratio	10.97
EPS	$27.87
Dividend Yield	0.00%
52-Week High	$373.69
52-Week Low	$211.43
Volume	85.09K
Avg Volume	0
Revenue (TTM)	$2.58B
Net Income	$759.90M
Gross Margin	51.87%

BIO Analyst Consensus

3 analysts cover BIO: 0 strong buy, 1 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $301.67.

Common questions about BIO

What are BIO's key financials?: BIO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BIO recently traded at $313.11. Market cap is $8.07B. P/E ratio is 10.97. Revenue is $2.58B.
Is BIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BIO. It does not provide personalized investment advice.